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June 11, 2013:2391–6was 63.3  13.3 years; 54% were men, 19% had diabetes, and
22% had known coronary artery disease, defined as a history of
myocardial infarction or prior coronary revascularization. The
stress echocardiograms were performed for evaluation of chest pain
or dyspnea in 55% of patients, preoperative assessment in 27%,
evaluation of known coronary artery disease in 10%, and other
reasons in 8%.
There was a significant association between the size of the left
atrium and abnormal stress echocardiographic results (Fig. 1). The
arger the left atrium, the greater the likelihood that the stress
chocardiogram would be abnormal (p  0.0001) or that there
ould be echocardiographic evidence of stress-induced ischemia
p  0.0001).
However, among patients with normal-sized atria (28
ml/m2), 23% had abnormal stress echocardiograms (ischemic,
ixed, or fixed) and 17% were positive for stress-induced
yocardial ischemia (ischemic or mixed). Even among patients
ith the smallest left atrial volumes (LAVI 20 ml/m2), 14%
were positive for stress-induced myocardial ischemia.
In this large population referred for clinically indicated stress
echocardiography, there was an association between the size of the
left atrium and stress echocardiographic findings in that the larger
the left atrium, the greater the likelihood that stress echocardio-
grams would be abnormal. However, patients who had normal left
atrial size also had abnormal or positive stress echocardiographic
results (23% and 17%, respectively) in this study. Thus, the
findings of a normal-sized left atrium on echocardiography should
not be used as a surrogate for predicting the absence of stress-
induced myocardial ischemia.
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Letters to the Editor
Simvastatin Effects
on Skeletal Muscle
Study Design and Validity
We read with great interest the report by Larsen et al. (1). In their
paper, they addressed a potential mechanism for statin-induced
myositis. This is a topic of clinical importance because muscle pain
is a common symptom for patients taking statins and the pain
often limits statin usage (2). Their physiological assessment of
individual patients was detailed and sophisticated. However, we
question their conclusion that simvastatin is the cause of the
muscle abnormalities they identified.
In their study, they compared Q10 content and maximal
oxidative phosphorylation (OXPHOS) capacity in 10 patients with
hypercholesterolemia who were taking simvastatin for at least 12
months with that in 9 healthy control volunteers with matched
age, weight, body mass index, fat percentage, and maximal oxygen
uptake. Our concern is that patients who take statins differ in many
clinical ways from healthy control individuals. These differences
between cases and controls are not likely to be balanced in the
matching, but they are likely to explain the difference in Q10
content and maximal OXPHOS capacity that the authors found.
For example, hyperlipidemia itself, preexisting metabolic syn-
drome, or other clinical conditions might alter coenzyme Q10
concentrations and cause the other physiological abnormalities
they identified. That such an explanation is likely is suggested by
the observation that patients with diabetes have altered Q10
concentrations (3). In the absence of a crossover study design or
selection of more appropriate case and control individuals, the
researchers’ conclusions do not seem valid.
The paper also suggested that the observed changes in coen-
zyme Q10 deficiency explained the myalgia, but this is speculative,
particularly because coenzyme Q10 supplementation has not been
consistently shown to alleviate statin-induced myopathy (4,5).
We applaud the authors for focusing their sophisticated phys-
ological methods on statin-associated myositis. We hope that they
nd others will apply these methods in patients using a more
ppropriate study design that will isolate any effects of long-term
tatin therapy from preexisting medical or other clinically relevant
onditions of patients (6).
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Reply
We appreciate the comments from Drs. Bode and Simpson
regarding our report on simvastatin’s effect on skeletal muscle.
We agree that a crossover design would be a more optimal
approach. However, we did find that the case patients and control
individuals were appropriately and close to optimally matched
when the present design was applied.
The inherent “clinical” differences between case and control indi-
viduals as Drs. Bode and Simpson suggested are possible but in our
minds unlikely. In support for their contention, they cited a paper for
finding alterations in coenzyme Q10 concentrations in patients with
diabetes, but unfortunately the essential information of whether these
patients were being treated with statins is lacking (1).
We do not claim to have proven that a decrease in coenzyme
10 content is instrumental in the myalgia. Rather, we wrote that
he impaired oxidative phosphorylation capacity was a plausible
echanistic explanation for the muscle pain.
A study conducted in mice showed that treatment with a
ipophilic statin (atorvastatin) impaired mitochondrial activity
NADH oxidase activity) as well as ubiquinone content without an
ffect on mitochondrial density, compared with control mice (2).
This was reversed with coenzyme Q10 supplementation (2). This
tudy confirmed that the statin treatment itself had the negative
ffect on skeletal muscle (2), as we reported in our study (3).
owever, overall reports on the effects of coenzyme Q10 supple-
entation on myalgia are ambiguous (4,5), but none of these
tudies investigated coenzyme Q10 content in human skeletal
uscle.
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Issues Needing Clarification
Regarding Population
Characteristics in the Analysis
From the National Cardiovascular
Data Registry
We read with interest the paper by Baklanov et al. (1), but we
think that some issues need to be clarified regarding the population
characteristics of the Prevalence and Outcomes of Transradial
Percutaneous Coronary Intervention for ST-Segment Elevation
Myocardial Infarction: Analysis From the National Cardiovascular
Data Registry (2007 to 2011).
First, there is no information about sheath sizes used in the
study groups. One of the endpoints was bleeding, and overt
access site bleeding and retroperitoneal hemorrhage within 72 h
of percutaneous coronary intervention (PCI) were included in
the definition of bleeding. Doyle et al. (2) reported that using
sheath sizes 6-F was identified as a strong independent
predictor of major femoral bleeding. Trimarchi et al. (3)
eported that adopting a sheath size of 8-F or larger was
ndependently related to independent predictors of retroperito-
eal hematoma after PCI.
Second, the incidence of high-risk C-type coronary lesions was
ignificantly greater in the femoral access group compared with the
adial access group. Barbash et al. (4) concluded that a type-C
oronary lesion was an angiographic predictor of PCI failure for
T-segment elevation myocardial infarction. In addition, Wilen-
ky et al. (5) reported that PCI for complex lesions was associated
ith increased in-hospital mortality. When considering that PCI
uccess and mortality were defined as primary endpoints of the
tudy, results may be affected because of this difference between
roups.
